Ris-Rez

BIOLOGICAL3 trials

Sponsors

GlaxoSmithKline

Conditions

NeoplasmsNeoplasms, LungSarcoma

Phase 1

A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

RecruitingNCT06551142

GlaxoSmithKlineNeoplasms

Start: 2024-09-30End: 2029-06-08Target: 845Updated: 2026-05-22

A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)

RecruitingNCT07602777

GlaxoSmithKlineSarcoma

Start: 2026-06-22End: 2029-11-23Target: 113Updated: 2026-07-15

Phase 3

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)

RecruitingNCT07099898

GlaxoSmithKlineNeoplasms, Lung

Start: 2025-08-11End: 2029-09-28Target: 420Updated: 2026-08-31

Related Papers

Abstract CT195: A phase 1 dose escalation/expansion study of GSK5764227, a B7-homolog 3 protein targeted antibody-drug conjugate, in combination with standard of care in patients with advanced solid tumors

Cancer Research2025-04-25

A phase 1 dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors, including gastrointestinal (GI) cancers.

Journal of Clinical Oncology2025-01-273 citations